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309use criteria (3) for noninvasive imaging, including myocardial
perfusion scintigraphy (MPS), stress echocardiography
(STE), and coronary computed tomographic angiography
(CCTA) (4–6). The application of ACC AUC for MPS,
STE, and CCTA has been studied in a variety of single-
modality settings, with a non-negligible rate of inappro-
priate testing reported (7–12). To date, interventions to
improve appropriateness of testing have not demonstrated
systematic improvement in patterns of performance (11). In
lieu of ACC AUC to guide test performance, most private
payers employ radiology beneﬁts managers (RBMs) for
utilization management who require prior authorization for
noninvasive CAD imaging (13). Concerns regarding the
clinical and economic value of RBMs have been raised,
including vendor variability; lack of transparency of proprie-
tary criteria for authorization of imaging; administrative
burden and associated costs; and lack of data to support long-
term cost effectiveness (14–16).
In this study, we evaluated the use of an automated, web-
based, point-of-order multimodality AUC decision support
tool (AUC-DST) in an RBM-free setting for determining
rates of appropriateness for noninvasive CAD imaging tests,
as well as the impact of the AUC-DST on intended down-
stream clinical decision making and testing utilization.Methods
Appropriate use criteria decision support tool. An app-
ropriate use criteria decision support tool (AUC-DST) was
developed based upon the most currently available ACC
AUC for MPS (2009), STE (2008), and CCTA (2010) at
the onset of the study (4–6). The AUC-DST is a web-based
application speciﬁcally developed for this study (MDDX,
San Francisco, California). The user interface was created
using a cross-platform compatible language (Flex and
ActionScript, Adobe Systems, San Jose, California) with
a SQL database backend (Microsoft, Redmond, Wash-
ington). Indications for each procedure were extracted from
the tables of each AUC document and were manually con-
verted to a stepwise decision tree format before coding into
the software program. Pop-up calculators were attached to
pertinent indications in the decision tree to assist the user in
accurately answering the next step in the decision tree.
Calculator types included pre-test likelihood of disease and
Framingham Risk Score. All data collected by the tool were
stored in a MySQL database (Oracle, Redwood City, Cal-
ifornia). The application was hosted at Hosting.com
(Denver, Colorado). All users were assigned unique logins.
Utilization timing, click paths, software-derived AUC
rulings, and manual override justiﬁcations were recorded
along with each user session.
The AUC-DST included all AUC indications speciﬁc to
CAD evaluation using a tree-and-node algorithm to assign
a level of appropriateness of CAD testing byAUC for patients
based upon modality type, CAD risk factors, level of pre-test
likelihood or risk of CAD, clinical presentation, and speciﬁcclinical scenario. Users navigated
the AUC-DST to determine the
level of appropriateness of a CAD
imaging test using a minimal
number of “clicks” within a dyna-
mic graphic user interface (Online
Fig. 1). When risk estimation was
required, the AUC-DST offered
optional calculators as recom-
mended by the AUC (17,18). If a
speciﬁc patient was not addressed
by AUC criteria, the AUC-DST
generated an appropriateness cat-
egory of “not addressed.” Tests
rated by the AUC-DST as non-
appropriate (uncertain, inappro-
priate, or not addressed) resulted
in a prompt to the ordering phy-
sician, who was then allowed to provide the reason for
disagreement with the rating.
Study design. We performed a prospective multicenter
cohort study of the AUC-DST to collect AUC ratings for
consecutive noninvasive CAD imaging tests covered by a
large, single, private payer for non-Medicare individuals
(United HealthCare, Minneapolis, Minnesota) from 3
single-specialty cardiology practice sites within 1 large
metropolitan area (St. Louis, Missouri) between June 2010
and January 2011. During the study period, the payer
allowed participating physicians within the demonstration
project who agreed to use the AUC-DST an exemption
from RBM prior authorization for noninvasive CAD
imaging tests, irrespective of the level of appropriateness
determined by the AUC-DST. Physicians prospectively
entered CAD risk factors and history at the time of AUC-
DST use. CAD risk factors and history were categorized as
binary variables, and symptom presentation was classiﬁed as
typical, atypical, noncardiac, or asymptomatic as previously
described (19). Physicians submitted test results and plans for
further management after test performance. The study was
approved at each of the cardiology practices by their institu-
tional review board.
Study physicians and patient population. Physicians and
practices were chosen for study participation based upon
the following inclusion criteria: 1) employment within 1 of
3 large, single-specialty cardiology practices within 1 large
metro area; 2)>500 CAD imaging tests per year per practice;
3) tests ordered were for patients with suspected CAD; 4)
tests ordered were for patients who possessed primary
coverage by non-Medicare United HealthCare; and 5)
agreement by all physicians within the practice to use the
AUC-DST in lieu of RBM prior authorization for the entire
duration of the study.
Tests ordered by physicians outside of the practice were
not included. Similarly, tests ordered for patients with sus-
pected CAD who were covered by payers other than United
HealthCare were not included in the present study.
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310Test results and proposed follow-up. After test perfor-
mance, physicians submitted noninvasive CAD imaging test
results and intended downstream management plans to the
AUC-DST. Test results were categorized as normal, mildly
abnormal, moderately abnormal, or severely abnormal.
For MPS and STE, this corresponded to 1% to 5%, 5% to
9.9%, or 10% ischemic myocardium or 1, 2 to 3, or >3
myocardial segments exhibiting stress-induced wall motion
abnormalities, respectively (20,21). For CCTA, mildly,
moderately, and severely abnormal were deﬁned by a max-
imal per-patient stenosis <50%, 50% to 70%, and 70%,
respectively (22). For treatment plans, ordering physicians
indicated their intention to perform or not perform addi-
tional diagnostic testing, inclusive of invasive coronary
angiography (with or without intended revascularization)
and further noninvasive CAD testing. Ordering physicians
also indicated their intention to intensify or not intensify
medical therapy independent of further testing.
Statistical analysis. Categorical variables are reported as
frequencies and percentages, and compared using the
Pearson chi-square test or, where there were cell counts <6,
the Fisher exact test. Continuous variables are reported as
means and standard deviations, and compared using the
2-sample Student t test or Wilcoxon rank sum test, as
appropriate. For comparisons with more than 2 categories, if
signiﬁcant associations were found, additional exploratory
chi-square tests were conducted for all pairwise comparisons
at each level using a Bonferroni-adjusted p value, and salient
results were reported. The Cochran-Armitage test for trend
and Cuzick test for trend were used to compare categorical
and continuous variables across temporally ordered groups,
respectively. We estimated that in order to detect a relative
decrease of 20% in inappropriate testing with 80% power,
this study would require 120 patients in each group between
the ﬁrst and last observation period. A 2-sided p < 0.05 was
considered statistically signiﬁcant. All analyses were per-
formed with SAS (version 9.2, SAS Institute, Cary, North
Carolina). F.Y.L. and J.K.M. were solely responsible for
the design and conduct of the study, had full access to all
the data in the study, and take responsibility for the integrityTable 1 Baseline Characteristics
Clinical Characteristic
Overall
(N ¼ 472)
MPS
(n ¼ 338
Age, yrs 55.6 (9.6) 57.3 (8.0)
Male 287 (61%) 222 (66%
Hyperlipidemia 328 (69%) 258 (76%
Diabetes 98 (21%) 86 (25%
Hypertension 316 (67%) 258 (76%
Family history of CAD 235 (50%) 183 (54%
Smoker 170 (36%) 130 (38%
Peripheral artery disease 24 (5%) 22 (7%)
Prior known CAD 191 (40%) 165 (49%
Post-menopausal (among women) 74 (40%) 50 (15%
*Fisher exact test applied to comparisons involving cell counts <6.
CAD ¼ coronary artery disease; CCTA ¼ cardiac computed tomographic angiography; MPS ¼ myocarof the data and the accuracy of the data analysis and
manuscript.Results
Baseline characteristics and ordering patterns. At 3
single-specialty cardiology practices, 100 physicians utilized
the AUC-DST for 8 months and 472 patients (age 55.6 9.6
years, 61% male, 52% prior CAD). Physicians ordered
testing for patients most frequently for MPS (n ¼ 338,
72%), followed by STE (n ¼ 111, 24%) and then CCTA
(n ¼ 23, 5%). Among the 100 participating physicians, 94
ordered 1 MPS, 38 ordered 1 STE, and 8 ordered 1
CCTA. Patients for whom MPS was ordered were
signiﬁcantly older, had a higher burden of CAD risk
factors, and had a higher prevalence of prior known CAD
when compared with patients for whom STE or CCTA
was ordered (Table 1).
AUC-DST use, clinical scenarios, and level of appro-
priateness. The distribution of AUC-DST use by most
common clinical scenarios and levels of appropriateness are
shown in Table 2. The chi-square or Fisher exact p values
represent the 2  3 comparisons of each level versus the
other levels combined. The AUC-DST required 137  360
s from the time of the initial modality selection to reach
a recommendation of appropriateness category. Level of
appropriateness required <60 s for 247 (52%) test cases. The
most common AUC categories used were “Symptomatic
detection of CAD” (37%), followed by “Asymptomatic
detection of CAD” (26%), and “Prior revascularization
(26%).” Bonferroni-adjusted pairwise comparisons (3 for
each statistically signiﬁcant level) showed that for “Asymp-
tomatic detection of CAD,” “Symptomatic detection of
CAD,” “Prior testing,” and “Other,” the CCTA group was
signiﬁcantly different from the STE test group, and in the
case of “Asymptomatic detection of CAD” and “Other,” was
also signiﬁcantly different from the MPS group. By the
AUC-DST, 51% of the 472 tests were appropriate, 20%
were uncertain, 18% were inappropriate, and 11% were not
addressed by AUC. Pairwise comparisons here showed that)
STE
(n ¼ 111)
CCTA
(n ¼ 23) p Value*
51.4 (11.6) 50.3 (12.8) <0.0001
) 51 (46%) 14 (61%) 0.0011
) 58 (52%) 12 (52%) <0.0001
) 12 (11%) 0 (0%) 0.0002
) 49 (44%) 9 (39%) <0.0001
) 49 (44%) 3 (13%) 0.0003
) 37 (33%) 3 (13%) 0.04
2 (2%) 0 (0%) 0.08
) 24 (22%) 2 (9%) <0.0001
) 20 (18%) 4 (17%) 0.22
dial perfusion single-photon emission computed tomography; STE ¼ stress echocardiography.
Table 2 Differences in Indications and Appropriateness Among Modalities
Clinical Classiﬁcation of Indication/AUC-DST Node Overall MPS STE CCTA p Value*
Asymptomatic (detection of CAD) 125 (26) 90 (27) 35 (32) 0 (0) 0.002
Symptomatic (detection of CAD) 173 (37) 107 (32) 60 (54) 6 (26) <0.001
Past revascularization 121 (26) 105 (31) 11 (10) 5 (22) <0.001
Acute coronary syndrome 9 (2) 8 (2) 1 (1) 0 (0) 0.66
Pre-operative evaluation 16 (3) 14 (4) 2 (2) 0 (0) 0.49
Prior test results 16 (3) 12 (4) 1 (1) 3 (13) 0.02
Other 12 (3) 2 (1) 1 (1) 9 (39) <0.001
Appropriateness rating
Appropriate 241 (51) 178 (53) 50 (45) 13 (57) 0.33
Uncertain 96 (20) 90 (27) 2 (2) 4 (17) <0.001
Inappropriate 85 (18) 44 (13) 40 (36) 1 (4) <0.001
Not addressed 50 (11) 26 (8) 19 (17) 5 (22) 0.004
Values are n (%). *Fisher exact test applied to comparisons involving cell counts <6. *Global chi-square with 12 degrees of freedom ¼ 173.4; p value <0.001. **Global chi-square with 6
degrees of freedom ¼ 63.4; p value <0.001.
AUC ¼ appropriate use criteria; DST ¼ decision support tool; other abbreviations as in Table 1.
JACC Vol. 62, No. 4, 2013 Lin et al.
July 23, 2013:308–16 Appropriate Use Criteria Decision Support Tool
311the STE group was signiﬁcantly different from both the
MPS and CCTA tests for uncertain or inappropriate tests.
Among all tests ordered, the 3 most common clinical
indications used were for MPS, reﬂecting the greater use of
MPS, and comprised 26% of all studies (Table 3). The most
common appropriate clinical indication for which any CAD
imaging test was ordered was for “Detection of CAD in
symptomatic patient with intermediate pre-test probability
of CAD, ECG interpretable, and able to exercise” by MPS
(10% of all studies), whereas the most common uncertain
indication was “Risk assessment post-revascularization in
asymptomatic patient 2 years post-PCI” by MPS (7% of
all studies), whereas the most common inappropriate indi-
cation was for “Detection of CAD in asymptomatic patient
with low CHD risk (Framingham risk criteria)” by STE
(4% of all studies). More than half of the studies considered
inappropriate (56% of all studies) were for clinical scenarios
addressing 3 low-risk patient types, including: 1) detection
of CAD in asymptomatic patients with low CHD riskTable 3 Most Common Indications by Modality and Appropriateness
Modality n (%)* Des
MPS
(n ¼ 338)
49 (10) Detection of CAD in symptomatic patient with intermed
and able to exercise
40 (8) Risk assessment post-revascularization in symptomatic
35 (7) Risk assessment post-revascularization in asymptomatic
STE
(n ¼ 111)
20 (4) Detection of CAD in symptomatic patient with intermed
and able to exercise
18 (4) Detection of CAD in asymptomatic patient with low CHD
14 (3) Detection of CAD in acute chest pain with intermediate
and negative cardiac enzymes
CCTA
(n ¼ 23)
5 (1) Evaluation of pulmonary vein anatomy prior to invasive
3 (0.6) Detection of CAD in symptomatic patient with intermed
and able to exercise
3 (0.6) Evaluation of suspected coronary artery anomalies
*As a percentage of all 427 tests.
A ¼ appropriate; CHD ¼ coronary heart disease; ECG ¼ electrocardiogram; I ¼ inappropriate; PCI ¼ p(MPS) (n ¼ 21); 2) detection of CAD in asymptomatic
patients with low CHD risk (STE) (n ¼ 18); and 3)
detection of CAD in symptomatic patients with low pre-test
probability of CAD and able to exercise (STE) (n ¼ 9).
Ordered MPS, STE, and CCTA did not differ signiﬁ-
cantly with respect to the frequency of studies categorized as
appropriate (p ¼ 0.33). MPS tests ordered were more likely
to be considered uncertain compared with STE or CCTA
(27% for MPS vs. 2% for STE and 17% for CCTA; p< 0.01).
STE tests ordered were most likely to be considered
inappropriate (36% for STE vs. 13% for MPS and 4% for
CCTA, p < 0.01), whereas CCTA tests ordered were most
likely to be not addressed (8% for MPS vs. 17% for STE and
22% for CCTA, p ¼ 0.004).
Physician disagreement with AUC-DST. For studies
considered nonappropriate, physicians provided their ratio-
nale for test ordering for 48 (21%) of cases. Among these,
physicians considered the AUC incorrect for 35%, and
estimated the pre-test likelihood or risk of patients higherRating
cription Appropriateness
iate pre-test probability of CAD, ECG interpretable, A
patient A
patient 2 years post-PCI U
iate pre-test probability of CAD, ECG interpretable, A
risk (Framingham risk criteria) I
pre-test probability of CAD, no dynamic ST-segment changes, A
radiofrequency ablation for atrial ﬁbrillation A
iate pretest probability of CAD, ECG interpretable, U
A
ercutaneous coronary intervention; U ¼ uncertain; other abbreviations as in Table 1.
Lin et al. JACC Vol. 62, No. 4, 2013
Appropriate Use Criteria Decision Support Tool July 23, 2013:308–16
312than the AUC for 48%. For 17% of nonappropriate cases,
physicians felt that their speciﬁc patient did not ﬁt ideally
into the clinical scenario described by the AUC-DST.
Test ﬁndings and intended downstream treatment plan. Of
472 tests, it was reported that physicians did not have
available results or further plans for testing in 22 (4.7%).
From the remaining 450 examinations, 48% were reported
as abnormal. Among test types, CCTA was most likely to
be abnormal (50%), followed by MPS (47%) and STE
(10%) (p < 0.01). Studies rated uncertain (56%) were most
likely to be abnormal, followed by appropriate (37%), not
addressed (30%), and inappropriate (28%, p < 0.01).
Nonappropriate studies were no more or less likely to be
abnormal than appropriate studies (Table 4).
Overall, physicians planned no further testing for 76%
patients, but intended to intensify medical therapy for 25%
patients. For normal tests, physicians were more likely to do
no further testing than for abnormal tests (99% vs. 41%, p <
0.01) and less likely to intensify medical therapy (15% vs.
40%; p < 0.01). There was no difference in plans for further
testing by level of appropriateness (80% for appropriate, 69%
for uncertain, 76% for inappropriate, 79% for not addressed;
p ¼ 0.23). Physicians were less likely to plan medical therapy
changes for patients whose testing was inappropriate (28%
for appropriate, 33% for uncertain, 9% for inappropriate, and
21% for not addressed; p ¼ 0.001).
Changes in tests and test results after use of the AUC-
DST. There was no signiﬁcant trend in the duration
required to complete the DST over the 4 observation
periods, nor were changes observed for patient age, number
of CAD risk factors, or frequency of prior CAD over time
(test for trend p > 0.05 for all).Table 4 Likelihood of an Abnormal Result by Appropriateness Among
Indication Appropriate Uncertain
Asymptomatic (detection of CAD)
Overall 2/15 (13) 18/40 (45)
MPS 2/13 (15) 17/39 (53)
STE 0/2 (0) 1/1 (100)
CCTA 0/0 (N/A) 0/0 (N/A)
Symptomatic (detection of CAD)
Overall 37/128 (29) 0/5 (0)
MPS 33/87 (38) 0/1 (0)
STE 4/41 (10) 0/1 (0)
CCTA 0/0 (N/A) 0/3 (0)
Prior revascularization
Overall 29/55 (53) 33/46 (72)
MPS 28/49 (57) 32/45 (71)
STE 0/4 (0) 0/0 (N/A)
CCTA 1/2 (50) 1/1 (100)
All other indications
Overall 18/35 (51) 0/0 (N/A)
MPS 14/24 (58) 0/0 (N/A)
STE 0/2 (0) 0/0 (N/A)
CCTA 4/9 (44) 0/0 (N/A)
Values are n abnormal/n total (%). N/A indicates that the total per cell ¼ 0 or insufﬁcient n to allow fo
Abbreviations as in Table 1.Across the 8-month study period, the frequency of
tests considered appropriate by the ACC AUC increased,
with a corresponding decline in the frequency of tests
considered inappropriate (p < 0.05 for both) (Fig. 1). The
frequency of inappropriate testing decreased from 22% in
the ﬁrst 2-month period to 6% in the last 2-month period
(p ¼ 0.0001), and appropriate studies increased from 49% in
the ﬁrst 2-month period to 61% in the last 2-month period
(p ¼ 0.02). Pertaining the MPS, the test type that
comprised nearly three-fourths of tests ordered, a signiﬁcant
reduction in test ordering occurred for indications consid-
ered inappropriate by ACC AUC between the ﬁrst and last
quarter (17% vs. 2%, p ¼ 0.002), with an accompanying
trend towards increased rates of appropriateness (49% vs.
62%, p ¼ 0.15).
The percentage of studies reported as normal or abnormal
did not change over time (Fig. 2). No signiﬁcant differences
were noted in the frequency of planned further testing across
the study period (p ¼ 0.30) (Fig. 3, blue bars). Plans for
medical therapy changes irrespective of further testing
increased from 11% to 32% from the ﬁrst 2 to the last 2
months, (p ¼ 0.001) (Fig. 3, red bars).Discussion
In this prospective, multicenter, observational cohort study, we
demonstrated that a web-based DST for AUC for noninvasive
CAD imaging to guide test ordering could be effectively
employed for an array of testing types and as a potential
alternative to RBMs. Use of the AUC-DST was associated
with increases in appropriate testing and decreases in inap-
propriate testing over an 8-month period. This AUC-DSTthe Most Common Indication Groups for Testing
Inappropriate Not Addressed p Value
11/47 (23) 6/18 (33) 0.07
7/21 (33) 6/14 (43) 0.30
4/26 (15) 0/4 (0) 0.08
0/0 (N/A) 0/0 (N/A) N/A
2/17 (12) 4/16 (25) 0.25
2/8 (25) 2/7 (29) 0.73
0/9 (0) 2/9 (22) 0.46
0/0 (N/A) 0/0 (N/A) N/A
4/8 (50) 1/5 (20) 0.06
3/5 (60) 0/0 (N/A) 0.37
0/2 (0) 0/4 (0) N/A
1/1 (100) 1/1 (100) 0.60
5/7 (71) 3/8 (38) 0.42
5/6 (83) 2/5 (40) 0.33
0/1 (0) 0/2 (0) N/A
0/0 (N/A*) 1/1 (100) 0.29
r comparison.
Figure 1
Changes in the Percentage of Studies at Each Level
of Appropriateness Using the AUC-DST From Q1 to Q4
of the Intervention
Appropriate studies increased in proportion whereas inappropriate studies
decreased. Quarter 1 (Q1) was the ﬁrst 2-month period, and Q4 was the last
2-month period. Global chi-square with 9 degrees of freedom ¼ 30.2;
p value <0.001. AUC-DST ¼ appropriate use criteria decision support tool.
Figure 3 Changes in Physician Treatment Plans Over Time
Planned medical therapy was deﬁned as maintenance or increase of medication
for coronary artery disease, without speciﬁc details on therapy, irrespective of
plans for testing. There was no change in plans for downstream testing over time,
whereas physician plans for medical therapy increased from quarter 1 (Q1) to Q4.
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313required an average of approximately 2 min for a physician to
determine the category of appropriateness, as regarded by
the ACC AUC. Further, the AUC-DST was deployed at the
point of order, thus providing physicians with instant
communication regarding appropriateness of testing. Given
the immediacy of feedback, the AUC-DST offered an
educational component as well, which may have been associ-
ated with the observed trends toward increased intended
changes in medical therapy changes without affecting inten-
ded rates of downstream testing. To our knowledge, this studyFigure 2
Changes in the Percentage of Studies With Normal
and Mildly, Moderately, or Severely Abnormal Results
Severity of abnormalities did not change over the time of the intervention. Global
chi-square with 9 degrees of freedom ¼ 6.7; p value ¼ 0.67. Q ¼ quarter.is the ﬁrst to evaluate the use of an AUC-DST to describe
behavior of physician-preferred over policy-based testing, as
well as the ﬁrst to relate levels of appropriateness across
multiple CAD imaging modalities to test results and future
intended treatment plans. Given the large number of par-
ticipating physicians from multiple community-based cardi-
ology practices, these results should be considered widely
generalizable and reﬂective of common clinical practice.
To our knowledge, this study is also the ﬁrst prospective
evaluation of an AUC-based DST in an unaffected envi-
ronment wherein physicians could perform any test, irre-
spective of appropriateness, without restrictions from RBM
prior authorization requirements. Notably, the physician-
preferred test ordering patterns enabled by the AUC-DST
was associated with an overall 18% rate of inappropriate
tests ordered, which is in keeping with the 15% to 20% of
RBM denials for prior authorization requests for advanced
imaging tests. As a potential advantage over RBMs, the
AUC-DST served as a continuous, immediate, educational
feedback mechanism to ordering physicians. We observed
a >20% increase and >75% decrease in rates of appropriate
and inappropriate testing, respectively, between the ﬁrst and
last quarters of the 8-month study. Across quarters, rates of
inappropriate tests ordered dropped from 22% to 6%. The
ﬁndings suggest that the AUC-DST may be an effective
alternative to policy-based prior authorization requirements
imposed by the RBM process, and may represent a method for
curbing inappropriate imaging with lesser administrative
burden, enhancing transparency of test authorization criteria,
improving test ordering in accordance with published AUC
documents, and serving as a continuous educational feedback
mechanism to ordering cardiologists. Direct comparative
studies of theAUC-DSTversusRBMs for test appropriateness,
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314as well as evaluation of the effects of the AUC-DST for non-
cardiologists, are nowwarranted. Further, because this study did
not evaluate the clinical and/or economic outcomes of the
AUC-DST against the standard of care method, these studies
are also now necessary.
Our study results differ from prior studies of cardiac
imaging test appropriateness. In a single-modality investi-
gation of MPS, Hendel et al. (11) observed no impact on the
frequency of appropriate, uncertain, or inappropriate MPS
following educational interventions that included optional
“on-demand reporting,” summary reports, blinded compar-
ison of test performance versus other clinical sites, sample
letters for distribution, and pocket cards. These results are in
accordance with those observed by Gibbons et al. (23) and
Willens et al. (24) for MPS and stress echocardiography,
respectively, wherein educational efforts such as grand rounds
and other presentations, newsletters, and meetings with
physician administrators were ineffective at reducing test
inappropriateness. By contrast, Chinnaiyan et al. (25) per-
formed a continuous quality improvement initiative for
coronary CT angiography in a statewide multicenter registry,
and observed reductions in inappropriate testing and
increases in appropriate testing when education was provided
to physicians in the context of losing coverage for CT.
The present study differs from each of these prior inves-
tigations in that patient- and scenario-speciﬁc educational
feedback was provided necessarily as a function of using the
AUC-DST in a manner that promoted learning and quality
improvement through “hands-on” usage rather than formal
didactics; continuously as opposed to sporadically; from
a multimodality rather than single-modality perspective; and
as a method for avoidance of time-consuming RBM
processes. Further, the AUC-DST used in the present study
communicated feedback at an earlier stage in the CAD
evaluation processdthat is, at the time of test orderingdwhen
alternative tests may be easily selected without communi-
cation delays that would occur later in a point-of-service
model within an imaging lab or even later at occasional
quality improvement meetings. It seems probable that
affecting change in ordering patterns must, in fact, be done
at the point of order rather than point of service. In addi-
tion, it appears effective if feedback is provided directly to
the ordering cardiologist provider over administrative or
ancillary staff that may have less familiarity with patient
presentation or AUC, as was performed in our study.
Further, we identiﬁed differences between test type and
appropriateness categories. Although no differences in
appropriateness were identiﬁed for MPS, STE, and CCTA,
MPS test ordering was more likely to be uncertain, STE
more likely to be inappropriate, and CCTA likely to be not
addressed. These ﬁndings may have occurred for a myriad of
reasons, including familiarity with the advantages and
limitations of the test type as well as the patient-speciﬁc level
of pre-test likelihood of CAD. Patterns were also observed
for speciﬁc clinical scenarios for level of appropriateness,
with 3 indications most commonly appropriate, 1 indicationfor uncertain, and 3 indications for inappropriate found to be
most common. These ﬁndings suggest that educational
intervention for inappropriate studies may be achievable by
education for a small number of scenarios.
An important criticism of AUC has been their lack of vali-
dation against outcomes (26). We observed a nonlinear rela-
tionship between increasing appropriateness and test normalcy,
likely reﬂecting the complexity and diversity of AUC indica-
tions. However, even within strata of asymptomatic patients,
we observed>10% abnormal test results among inappropriate
indications, similar to prior observations for rest transthoracic
echocardiography (12,27). In this regard, our study ﬁndings are
not inconsistent with prior studies. This imperfect negative
predictive value may be partially explained by the nonuniform
uptake of AUC in cardiology practice, as well as the possibility
that the likelihood of abnormality of a certain test does not
necessarily dictate its level of appropriateness. A simple
exemplary scenario is that of an asymptomatic patient with
a prior myocardial infarction who undergoes coronary artery
bypass surgery and subsequent nuclear single-photon emission
computed tomography imaging 6 months after surgery.
Although the perfusion deﬁcits associated with the prior infarct
will be observed by single-photon emission computed tomog-
raphy (thereby rendering the test “abnormal”), this application
is neither clinically valuable nor endorsed by the ACC AUC.
Importantly, the negative predictive value of proprietary RBM
guidelines is unknown. We also observed no differences in
intended downstream testing rates by level of appropriateness,
but a lower likelihood of medical therapy changes for inap-
propriate testing.Thus, the decreasingnumber of inappropriate
studies over the course of the interventionmayhave contributed
to the increase inmedical therapy over time. It is noteworthy to
mention that this study did not address the issue of downstream
test “layering” or CAD event utilization, such as for death,
myocardial infarction, or CAD-related hospitalization. The
ﬁndings have been evaluated by prior studies such as the
SPARC (Study of Myocardial Perfusion and Coronary
Anatomy Imaging Roles in Coronary Artery Disease) registry;
however, these studies have lacked information related to test
appropriateness (28).
To combat overuse or misuse of imaging, more than 90%
of the largest private payers have contracted with RBMs who
require prior authorization of imaging as a front-end safe-
guard to managing resources, a method that has demon-
strated success at reducing costs (13). Yet RBM requirements
for prior authorization have drawn objections from practi-
tioners and physician specialty societies, with contentions
that such proprietary approaches are not consistently rooted
in scientiﬁc evidence or published AUC; differ across or
within geographical regions; and are not uniformly trans-
parent (15). Critics of RBMs further contend that incentives
to reduce costs in a for-proﬁt environment may result in
indiscriminate reduction of medically necessary imaging,
unnecessary delays in healthcare delivery, and worsened
healthcare quality. By contrast, ACC AUC are developed
by a 2-step RAND method by a panel of experts and
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date. Further, no uniform method exists for obtaining prior
authorization across the multitude of RBMs, and additional
administrative resources are thus required, with $7,500 per
cardiologist per year estimated as necessary to accommodate
RBM requirements (14). Indeed, prior decision models
suggest that RBMs simply shift costs toward physician
practices, with an unknown impact on overall societal
healthcare costs (29).
Our study may be directly relevant to policymakers who
must balance the distribution of healthcare resources, with
noninvasive cardiac imaging highly consumptive and thus,
a high priority. Between 2000 and 2006, per-person imaging
costs in the United States experienced an almost 2-fold rate of
growth, which was twice as high as for other services to
Medicare beneﬁciaries and far in excess of growth in CAD
prevalence (13,30–32). Whether use of RBMs produces
salutary healthcare and economic outcomes has been a subject
of great debate, having been addressed in the recentMedicare
Improvement and Patient Protection Act, Congressional
budget proposals, the American Medical Association report
to Congress, and the ongoing Medicare Imaging Demon-
stration project (33–35). The results of our study suggest that
a computerized point-of-order decision support system can
reliably track physician behavior and that favorable changes
can occur, even in the absence of RBM prior authorization
requirements. Our results engender promise of the value of
such an AUC-DST for improving appropriate testing,
enhancing transparency, and reducing administrative burden.
At the same time, our study highlights challenges in directly
linking process measures to clinical outcomes.
Finally, the present study evaluated the test ordering
patterns solely for cardiologists, rather than noncardiologists
that include primary care physicians, emergency department
physicians, and other noncardiology specialists. Importantly,
prior studies, including that performed by Hendel et al. (11),
have demonstrated that rates of inappropriate test ordering
are higher in noncardiologists compared with cardiologists.
It seems feasible that the AUC-DST may have had a more
dramatic effect in test appropriateness had this study
included them.
Study limitations. First, although participating physicians
were exempt from prior authorization requirements during
the study, no direct comparison to RBMs was performed.
Thus, although we observed improvements in rates of
appropriate testing and reductions in rates of inappropriate
testing, the direct comparison of an AUC-DST versus RBMs
for test appropriateness rates, costs, and clinical outcomes now
appears warranted. Second, we tested the impact of an AUC-
DST alone without the confounding inﬂuence of payer-
designated RBMs. In doing so, our study was restricted to
tests ordered for individuals with primary payer coverage with
a waiver of RBM pre-authorization, which was offered only
for non-Medicare private payer–covered individuals. As such,
the generalizability of our study results to individuals covered
under other private or public payers should be done withcaution. In addition, because the payer only allowed the RBM
waiver as an alternative cost-containment strategy, a control
group without either an RBM or AUC-DST was not avail-
able for comparison. In this regard, it is possible a Hawthorne
effect may have applied, that is, simply informing providers
that their appropriateness would be observed and evaluated
may have been an intervention in itself. This effect, however,
has not been observed in prior studies such as that of Hendel
et al. (11). Third, we studied only the impact of the AUC-
DST for board-certiﬁed cardiologists, and whether our
results can be applied to primary care physicians or other
physician specialists cannot be deﬁnitively determined.
Because noncardiologists order approximately half of the
noninvasive tests for CAD, this is an important area of further
study (36). Fourth, as the AUC-DST follows the ACCAUC
criteria, it did not offer or compare alternative tests for the
same indication. More recent guidelines with uniform indi-
cation deﬁnitions across modalities may be more useful for
intermodality comparison. The anticipated multimodality
ACCAUC, whose publication is expected later this year, may
provide a more integrated guidance document for futures
studies. Finally, we ascertained test results and intended
changes in therapy, but lacked information related to long-
term health and economic outcomes.
Conclusions
An automated point-of-order AUC-DST successfully ad-
dressed most tests ordered for CAD evaluation, with rapid
provision of test-speciﬁc appropriateness. Use of the AUC-
DST was associated with an increase in appropriate testing
and a decrease in inappropriate testing. A point-of-order
AUC-DST may be a transparent, efﬁcient, and educa-
tional mechanism to guide imaging utilization for individ-
uals with suspected CAD.
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